Darglitazone (Sodium)

Darglitazone Sodium, a thiazolidinedione, is an orally active, potent, and selective PPAR-γ (peroxisome proliferator-activated receptor) agonist. Darglitazone Sodium is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research[1][2].

Product Specifications

CAS Number

[149904-87-0]

Product Name Alternative

CP 86325 (Sodium)

UNSPSC

12352005

Target

PPAR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/darglitazone-sodium.html

Solubility

10 mM in DMSO

Smiles

O=C([N-]1)SC(CC2=CC=C(C(CCC3=C(C)OC(C4=CC=CC=C4)=N3)=O)C=C2)C1=O.[Na+]

Molecular Formula

C23H19N2NaO4S

Molecular Weight

442.46

References & Citations

[1]Rashmi Kumari, et al. The PPAR-gamma agonist, darglitazone, restores acute inflammatory responses to cerebral hypoxia-ischemia in the diabetic ob/ob mouse. J Cereb Blood Flow Metab. 2010 Feb;30 (2) :352-60.|[2]Hoenig M, Ferguson DC. Effect of darglitazone on glucose clearance and lipid metabolism in obese cats. Am J Vet Res. 2003 Nov;64 (11) :1409-13.